580 related articles for article (PubMed ID: 18227491)
1. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
3. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
Pi-Sunyer FX; Aronne LJ; Heshmati HM; Devin J; Rosenstock J;
JAMA; 2006 Feb; 295(7):761-75. PubMed ID: 16478899
[TBL] [Abstract][Full Text] [Related]
4. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
Hollander P
Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
[TBL] [Abstract][Full Text] [Related]
5. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
Scheen AJ
J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
[TBL] [Abstract][Full Text] [Related]
6. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
[TBL] [Abstract][Full Text] [Related]
7. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP; Golay A; Sjöström L;
N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
[TBL] [Abstract][Full Text] [Related]
8. [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].
Scheen AJ; Van Gaal LG; Després JP; Pi-Sunyer X; Golay A; Hanotin C
Rev Med Suisse; 2006 Aug; 2(76):1916-23. PubMed ID: 16972542
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
Van Gaal LF; Scheen AJ; Rissanen AM; Rössner S; Hanotin C; Ziegler O;
Eur Heart J; 2008 Jul; 29(14):1761-71. PubMed ID: 18417461
[TBL] [Abstract][Full Text] [Related]
10. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.
Ruilope LM; Després JP; Scheen A; Pi-Sunyer X; Mancia G; Zanchetti A; Van Gaal L
J Hypertens; 2008 Feb; 26(2):357-67. PubMed ID: 18192851
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.
Scheen AJ; Finer N; Hollander P; Jensen MD; Van Gaal LF;
Lancet; 2006 Nov; 368(9548):1660-72. PubMed ID: 17098084
[TBL] [Abstract][Full Text] [Related]
12. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.
Christopoulou FD; Kiortsis DN
J Clin Pharm Ther; 2011 Feb; 36(1):10-8. PubMed ID: 21198716
[TBL] [Abstract][Full Text] [Related]
13. New approaches for the management of patients with multiple cardiometabolic risk factors.
Van Gaal LF; Peiffer F
J Endocrinol Invest; 2006; 29(3 Suppl):83-9. PubMed ID: 16751712
[TBL] [Abstract][Full Text] [Related]
14. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Després JP; Ross R; Boka G; Alméras N; Lemieux I;
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
[TBL] [Abstract][Full Text] [Related]
15. SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes.
Rosenstock J; Hollander P; Chevalier S; Iranmanesh A;
Diabetes Care; 2008 Nov; 31(11):2169-76. PubMed ID: 18678611
[TBL] [Abstract][Full Text] [Related]
16. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
Nissen SE; Nicholls SJ; Wolski K; Rodés-Cabau J; Cannon CP; Deanfield JE; Després JP; Kastelein JJ; Steinhubl SR; Kapadia S; Yasin M; Ruzyllo W; Gaudin C; Job B; Hu B; Bhatt DL; Lincoff AM; Tuzcu EM;
JAMA; 2008 Apr; 299(13):1547-60. PubMed ID: 18387931
[TBL] [Abstract][Full Text] [Related]
17. Rimonabant for overweight or obesity.
Curioni C; André C
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD006162. PubMed ID: 17054276
[TBL] [Abstract][Full Text] [Related]
18. Pleiotropic effects of rimonabant: clinical implications.
Després JP
Curr Pharm Des; 2009; 15(5):553-70. PubMed ID: 19199981
[TBL] [Abstract][Full Text] [Related]
19. [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2007 Feb; 62(2):81-5. PubMed ID: 17461296
[TBL] [Abstract][Full Text] [Related]
20. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Boekholdt SM; Jukema JW; Peters RJ
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
